Stock NB3 NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Neurocrine Biosciences, Inc. Deutsche Boerse AG

Equities

NB3

US64125C1099

Market Closed - Deutsche Boerse AG
Other stock markets
 17:28:09 31/05/2024 BST 		5-day change 1st Jan Change
124 EUR +0.61% Intraday chart for Neurocrine Biosciences, Inc. -4.36% +4.38%
05-31 Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing MT
05-28 Neurocrine Biosciences Says CEO Kevin Gorman Retiring MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing
Neurocrine Biosciences to Participate at Investor Conferences in June
Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
Neurocrine Biosciences Says CEO Kevin Gorman Retiring
Neurocrine founder-CEO Gorman to retire in October
Neurocrine CEO set to retire
Neurocrine Biosciences Announces CEO Succession Plan
Neurocrine Biosciences Announces CEO Changes
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis
Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. NB3 Stock
  5. News Neurocrine Biosciences, Inc.
  6. Other languages